Ketoprofen

製品コードS1645 バッチS164501

印刷

化学情報

Chemical Structure Synonyms RP-19583 Storage
(From the date of receipt)		 3 years -20°C powder
1 years -80°C in solvent
化学式

C16H14O3
分子量 254.28 CAS No. 22071-15-4
Solubility (25°C)* 体外 DMSO 51 mg/mL (200.56 mM)
Ethanol 51 mg/mL (200.56 mM)
Water Insoluble
体内 （毎回新しく調製した物を用意してください）
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明 Ketoprofen (RP-19583) は、関節炎関連の炎症性疼痛の治療に用いられる非ステロイド性抗炎症薬として使用される二重COX1/2阻害剤です。
in vitro Ketoprofen combined with UVB irradiation induces the cytotoxicity and suppresses DNA synthesis in HaCaT cells in a concentration-dependent manner. This compound combined with UVB irradiation inhibits the cell growth and induces G2/M cell cycle arrest by modulating the levels of cdc2, cyclin B1, Chk1, Tyr15-phosphorylated cdc2 and p21. It also provokes a striking accumulation of cyclin B1-cdc2-p21 complexes, concomitantly with an increase in the levels of Tyr15-phosphorylated cdc2 and p21 protein. This chemical combined with UVB irradiation accentuates the apoptotic response to UVB radiation in HaCaT cells as evidenced by DAPI staining.
in vivo Ketoprofen at 1% level in suitable topical vehicles can effectively inhibit GCF-LTB4 and GCF-PGE2 and positively alter alveolar bone activity in the ligature-induced model of periodontitis in the monkey. This compound (3.63 mg/kg bwt) reduces hoof pain andlameness to a greater extent than the 2.2 mg/kg dose and phenylbutazone. It is more effective than local anesthesia (LA), or caudal epidural anesthesia (EPI) in decreasing cortisol and partially reverses the reduction in average daily gain (ADG) following castration. This chemical (40 and 80 mg/kg diet) reduces the incidence of transitional cell carcinoma of the urinary bladder by >70% from that seen in dietary mice.

プロトコル(参考用のみ)

参考

  • https://pubmed.ncbi.nlm.nih.gov/17964538/
  • https://pubmed.ncbi.nlm.nih.gov/8971650/
  • https://pubmed.ncbi.nlm.nih.gov/8536666/
  • https://pubmed.ncbi.nlm.nih.gov/12772856/
  • https://pubmed.ncbi.nlm.nih.gov/8706245/

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

Protein C receptor maintains cancer stem cell properties via activating lipid synthesis in nasopharyngeal carcinoma [ Signal Transduction and Targeted Therapy, 2022, 46] PubMed: 35169126.0
Protein C receptor maintains cancer stem cell properties via activating lipid synthesis in nasopharyngeal carcinoma [ Signal Transduct Target Ther, 2022, 7(1):46] PubMed: 35169126
Repurposing [11C]PS13 for PET imaging of cyclooxygenase-1 (COX-1) in ovarian cancer xenograft mouse models [ Journal of Nuclear Medicine, 2021, 657-663] PubMed: 32978284.0
Repurposing [11C]PS13 for PET imaging of cyclooxygenase-1 (COX-1) in ovarian cancer xenograft mouse models [ J Nucl Med, 2020, jnumed.120.249367] PubMed: 32978284

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。